The Latest
-
magicmine, iStock / Getty Images Plus via Getty Images
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.
-
Alex Wong / Staff via Getty Images
HHS announces sweeping reorganization, including cuts of 10K workers
Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.
-
Win McNamee via Getty Images
Rx-to-OTC rule gets pushed back — again
A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.
-
Permission granted by Novavax
ProfileThe industry heavyweight behind Novavax’s push to bounce back
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
-
Jacob Bell/PharmaVoice
Biogen plots new global headquarters in Kendall Square
The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.
-
Scott Olson via Getty Images
Lilly, Novo expand DTC reach of obesity meds after compound win
The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.
-
Stock via Getty Images
Biotechs emerging from stealth take aim at pharma’s prime targets
The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.
-
Stock via Getty Images
How pharma could feel the pain of a recession
Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.
-
Courtesy of Sarepta
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.
-
Stock via Getty Images
The key factors shaping China’s biopharma boom
Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.
-
Joe Raedle via Getty Images
Vaccine makers face mRNA backlash as states seek further restrictions
A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.
-
Permission granted by Diakanos
Q&AHow non-traditional investors fuel up-and-coming biotechs when VC funding dries up
Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.
-
Stock via Getty Images
Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do
Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.
-
Permission granted by Roche
Q&ARoche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
-
Stock via Getty Images
Takeda’s $770M deal deepens Big Pharma’s omics push
The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.
-
Andrew Harnik / Staff via Getty Images
Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings
HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.
-
Win McNamee via Getty Images
IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?
Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.
-
Stock via Getty Images
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
-
Stock via Getty Images
Pricing transparency is in the spotlight — and that could be good news for drugmakers
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?
-
Permission granted by Biogen
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
-
iStock via Getty Images
As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges
Experts say cost and other barriers present challenges to returning to U.S. shores.
-
Kayla Bartkowski via Getty Images
How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?
With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.
-
iStock via Getty Images
The time is ripe for pharma M&A. Why are drugmakers holding out?
The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.
-
Kevin C. Cox via Getty Images
The top 3 impacts of Trump’s health data purge
Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.
-
Permission granted by Voyager Therapeutics
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.
